Literature DB >> 1172524

The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.

W Birkmayer, P Riederer, M B Youdim, W Linauer.   

Abstract

The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of monoamine oxidase (MAO) "B", Deprenil, has been demonstrated in parkinsonian patients with or without previous L-Dopa theapy. Application of the drug has been performed orally, intravenously and intramuscularly. Excellent kinetic effects resulted when combined with Madopar. The combined treatment with L-Dopa was highly effective when applicated i.v. or i.m. Deprenil is an inhibitor of MAO-B and is characterized by less frequent side effects. These are predominantly involuntary movements and confusion, which can be eliminated by lowering the dosage of Deprenil. A daily rhythm of MAO could be demonstrated in several areas of human brains as well as in a control group as in parkinsonian patients with or without L-Dopa therapy. Maximal activity of MAO occurs between noon and 6p.m. The clinical and biochemical data are discussed regarding the off-phenomenons as Deprenil is an excellent drug for preventing these.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1172524     DOI: 10.1007/bf01253131

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  43 in total

1.  Corticosteroid and growth hormone secretion in patients treated with L-dopa.

Authors:  K von Werder; G R van Loon; F Yatsu; P H Forsham
Journal:  Klin Wochenschr       Date:  1970-12-15

Review 2.  Effects of drugs and physiological factors in the disposition of catecholamines in blood vessels.

Authors:  S Spector; J Tarver; B Berkowitz
Journal:  Pharmacol Rev       Date:  1972-06       Impact factor: 25.468

3.  Plasma levodopa and the "on-off" effect.

Authors:  D B Caine; L E Claveria; J G Allen
Journal:  Adv Neurol       Date:  1974

4.  Short- and long-term approaches to the "on-off" phenomenon.

Authors:  P S Papavasiliou; G C Cotzias; I Mena
Journal:  Adv Neurol       Date:  1974

5.  The daily rhythm of HVA, VMA, (VA) and 5-HIAA in depression-syndrome.

Authors:  P Riederer; W Birkmayer; E Neumayer; L Ambrozi; W Linauer
Journal:  J Neural Transm       Date:  1974       Impact factor: 3.575

6.  Daily fluctuation (circadian and ultradian) in biogenic amines of the rat brain.

Authors:  L E Scheving; W H Harrison; P Gordon; J E Pauly
Journal:  Am J Physiol       Date:  1968-01

7.  Effect of pretreatment with oestradiol, progesterone and DOPA on monoamine oxidase activity in the rat.

Authors:  G G Collins; J Pryse-Davies; M Sandler; J Southgate
Journal:  Nature       Date:  1970-05-16       Impact factor: 49.962

8.  Relation of sex and aging to monoamine oxidase activity of human brain, plasma, and platelets.

Authors:  D S Robinson; J M Davis; A Nies; C L Ravaris; D Sylwester
Journal:  Arch Gen Psychiatry       Date:  1971-06

9.  A rapid microfluorimetric determination of monoamine oxidase.

Authors:  M Krajl
Journal:  Biochem Pharmacol       Date:  1965-11       Impact factor: 5.858

10.  The oestrous cycle and monoamine oxidase activity.

Authors:  M Holzbauer; M B Youdim
Journal:  Br J Pharmacol       Date:  1973-08       Impact factor: 8.739

View more
  89 in total

1.  The effects of deprenyl on methamphetamine-induced dopamine depletions.

Authors:  S K Johnson; D Medina; G C Wagner
Journal:  J Neural Transm Gen Sect       Date:  1992

Review 2.  Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.

Authors:  Anthony H V Schapira
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

Review 3.  The modern management of Parkinson's disease.

Authors:  N Quinn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-02       Impact factor: 10.154

Review 4.  Selegiline and Parkinson's disease. Protective and symptomatic considerations.

Authors:  L I Golbe; J W Langston; I Shoulson
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

5.  R-deprenyl: pharmacological spectrum of its activity.

Authors:  K Magyar; B Szende; V Jenei; T Tábi; M Pálfi; E Szöko
Journal:  Neurochem Res       Date:  2010-08-20       Impact factor: 3.996

6.  Restoration and putative protection in Parkinsonism.

Authors:  T Archer; A Fredriksson
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

7.  Changes in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration.

Authors:  K Baraczka; M I Fekete; B Kanyicska
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

8.  The effects of monoamine oxidase B inhibition on dopamine metabolism in rats with nigro-striatal lesions.

Authors:  E Scarr; D M Wingerchuk; A V Juorio; I A Paterson
Journal:  Neurochem Res       Date:  1994-02       Impact factor: 3.996

9.  Antiparkinsonian Agents : Clinically Significant Drug Interactions and Adverse Effects, and Their Management.

Authors:  A Dalvi; B Ford
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

10.  Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline.

Authors:  Zaid A Abassi; Ofer Binah; Moussa B H Youdim
Journal:  Br J Pharmacol       Date:  2004-08-31       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.